{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T04:01:13Z","timestamp":1790740873333,"version":"4.1.0"},"reference-count":33,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T00:00:00Z","timestamp":1785110400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100005010","name":"Associazione Italiana per la Ricerca sul Cancro","doi-asserted-by":"publisher","award":["IG#20-061"],"award-info":[{"award-number":["IG#20-061"]}],"id":[{"id":"10.13039\/501100005010","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003196","name":"Ministero della Salute","doi-asserted-by":"publisher","award":["RF-2021-12-371-961"],"award-info":[{"award-number":["RF-2021-12-371-961"]}],"id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Translational Oncology"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.tranon.2026.102960","type":"journal-article","created":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T17:48:27Z","timestamp":1785260907000},"page":"102960","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Time-varying hazard rates reveal patterns of progression in HR+\/HER2\u2013 metastatic breast cancer: Towards risk-adapted monitoring"],"prefix":"10.1016","volume":"72","author":[{"given":"Linda","family":"Cucciniello","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4160-3479","authenticated-orcid":false,"given":"Fabiola","family":"Giudici","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo","family":"Foffano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Franzoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brenno","family":"Past\u00f2","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-1979-5020","authenticated-orcid":false,"given":"Elisabetta","family":"Molteni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-4362-4889","authenticated-orcid":false,"given":"Serena","family":"Della Rossa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaetano","family":"Pascoletti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Spazzapan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorena","family":"Musco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriele","family":"Di Giustino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucia","family":"Da Ros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riccardo","family":"Vida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Poletto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Nascimbeni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3757-3702","authenticated-orcid":false,"given":"Marta","family":"Bonotto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Marco Minisini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2249-0285","authenticated-orcid":false,"given":"Barbara","family":"Belletti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Damante","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8313-4834","authenticated-orcid":false,"given":"Lorenzo","family":"Gerratana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0573-4938","authenticated-orcid":false,"given":"Fabio","family":"Puglisi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.tranon.2026.102960_bib0001","first-page":"209","article-title":"Global Cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.tranon.2026.102960_bib0002","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1634\/theoncologist.2014-0002","article-title":"Measures of outcome in metastatic breast cancer: insights from a real-world scenario","volume":"19","author":"Bonotto","year":"2014","journal-title":"Oncologist"},{"key":"10.1016\/j.tranon.2026.102960_bib0003","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1093\/annonc\/mdm271","article-title":"Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007","volume":"18","author":"Goldhirsch","year":"2007","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.tranon.2026.102960_bib0004","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1200\/JCO.19.02309","article-title":"Estrogen and progesterone receptor testing in breast cancer: ASCO\/CAP guideline update","volume":"38","author":"Allison","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.tranon.2026.102960_bib0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2022.102445","article-title":"Tailoring adjuvant endocrine therapy in early breast cancer: when, how, and how long?","volume":"110","author":"Cucciniello","year":"2022","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.tranon.2026.102960_bib0006","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1016\/j.annonc.2020.09.010","article-title":"5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5)","volume":"31","author":"Cardoso","year":"2020","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.tranon.2026.102960_bib0007","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1007\/s10549-018-05125-4","article-title":"Palbociclib plus letrozole as first-line therapy in estrogen receptor-positive\/human epidermal growth factor receptor 2-negative advanced breast cancer with extended follow-up","volume":"174","author":"Rugo","year":"2019","journal-title":"Breast. Cancer Res. Treat."},{"key":"10.1016\/j.tranon.2026.102960_bib0008","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1093\/annonc\/mdy155","article-title":"Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer","volume":"29","author":"Hortobagyi","year":"2018","journal-title":"Ann. Oncol. Off. J. Eur. Soc. Med. Oncol."},{"key":"10.1016\/j.tranon.2026.102960_bib0009","doi-asserted-by":"crossref","DOI":"10.1016\/j.annonc.2022.08.009","article-title":"LBA15 MONARCH 3: interim overall survival (OS) results of abemaciclib plus a nonsteroidal aromatase inhibitor (NSAI) in patients (pts) with HR+, HER2- advanced breast cancer (ABC)","volume":"33","author":"Goetz","year":"2022","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.tranon.2026.102960_bib0010","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2022.40.17_suppl.LBA1003","article-title":"Overall survival (OS) with first-line palbociclib plus letrozole (PAL+LET) versus placebo plus letrozole (PBO+LET) in women with estrogen receptor\u2013positive\/human epidermal growth factor receptor 2\u2013negative advanced breast cancer (ER+\/HER2\u2212 ABC): analyses","volume":"40","author":"Finn","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.tranon.2026.102960_bib0011","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1056\/NEJMoa2114663","article-title":"Overall survival with Ribociclib plus letrozole in advanced breast cancer","volume":"386","author":"Hortobagyi","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.tranon.2026.102960_bib0012","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1016\/j.annonc.2024.04.013","article-title":"Abemaciclib plus a nonsteroidal aromatase inhibitor as initial therapy for HR+, HER2\u2212 advanced breast cancer: final overall survival results of MONARCH 3","volume":"35","author":"Goetz","year":"2024","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.tranon.2026.102960_bib0013","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.2217\/fon-2020-0020","article-title":"Clinico-radiological monitoring strategies in patients with metastatic breast cancer: a real-world study","volume":"16","author":"Bonotto","year":"2020","journal-title":"Futur. Oncol."},{"key":"10.1016\/j.tranon.2026.102960_bib0014","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1016\/j.annonc.2021.09.019","article-title":"ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer","volume":"32","author":"Gennari","year":"2021","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.tranon.2026.102960_bib0015","article-title":"NCCN Guidelines Index table of Contents DIscussion","volume":"Version 4","author":"Gradishar","year":"2025","journal-title":"Breast. Cancer"},{"key":"10.1016\/j.tranon.2026.102960_bib0016","doi-asserted-by":"crossref","first-page":"2820","DOI":"10.1200\/JCO.2016.66.6313","article-title":"Use and costs of disease monitoring in women with metastatic breast cancer","volume":"34","author":"Accordino","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.tranon.2026.102960_bib0017","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2020.550185","article-title":"Plasma-based longitudinal evaluation of ESR1 epigenetic status in hormone receptor-positive HER2-negative metastatic breast cancer","volume":"10","author":"Gerratana","year":"2020","journal-title":"Front. Oncol."},{"key":"10.1016\/j.tranon.2026.102960_bib0018","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1002\/path.5584","article-title":"<scp>CDKN1B <\/scp>mutation and copy number variation are associated with tumor aggressiveness in luminal breast cancer","volume":"253","author":"Viotto","year":"2021","journal-title":"J. Pathol."},{"key":"10.1016\/j.tranon.2026.102960_bib0019","doi-asserted-by":"crossref","first-page":"114","DOI":"10.32614\/RJ-2014-028","article-title":"Bshazard: A flexible tool for nonparametric smoothing of the hazard function","volume":"6","author":"Rebora","year":"2014","journal-title":"R. J."},{"key":"10.1016\/j.tranon.2026.102960_bib0020","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.ejca.2021.12.031","article-title":"Impact of lobular versus ductal histology on overall survival in metastatic breast cancer: a French retrospective multicentre cohort study","volume":"164","author":"Dalenc","year":"2022","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.tranon.2026.102960_bib0021","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1186\/s13244-021-01120-4","article-title":"Infiltrative pattern of metastatic invasive lobular breast carcinoma in the abdomen: a pictorial review","volume":"12","author":"Wong","year":"2021","journal-title":"Insights. ImAging"},{"key":"10.1016\/j.tranon.2026.102960_bib0022","doi-asserted-by":"crossref","first-page":"39","DOI":"10.3233\/BD-2009-0280","article-title":"Distinct clinical and prognostic features of invasive lobular breast cancer","volume":"30","author":"Petrausch","year":"2009","journal-title":"Breast. Dis."},{"key":"10.1016\/j.tranon.2026.102960_bib0023","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1007\/s10549-013-2711-y","article-title":"Prognosis of metastatic breast cancer subtypes: the hormone receptor\/HER2-positive subtype is associated with the most favorable outcome","volume":"141","author":"Lobbezoo","year":"2013","journal-title":"Breast. Cancer Res. Treat."},{"key":"10.1016\/j.tranon.2026.102960_bib0024","article-title":"Invasive lobular carcinoma of the breast: a special histological type compared with invasive ductal carcinoma","volume":"12","author":"Chen","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.tranon.2026.102960_bib0025","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1634\/theoncologist.2018-0176","article-title":"Prognostic value of the progesterone receptor by subtype in patients with estrogen receptor-positive, HER-2 negative breast cancer","volume":"24","author":"Van Asten","year":"2019","journal-title":"Oncologist"},{"key":"10.1016\/j.tranon.2026.102960_bib0026","article-title":"Clinicopathological characteristics and breast cancer\u2013Specific survival of patients with single hormone receptor\u2013Positive breast cancer","volume":"3","author":"Li","year":"2020","journal-title":"JAMA Netw. Open."},{"key":"10.1016\/j.tranon.2026.102960_bib0027","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1093\/jncimonographs\/lgu024","article-title":"Cancer survival: an overview of measures, uses, and interpretation","volume":"2014","author":"Mariotto","year":"2014","journal-title":"JNCI Monogr."},{"key":"10.1016\/j.tranon.2026.102960_bib0028","doi-asserted-by":"crossref","first-page":"5272","DOI":"10.1002\/cncr.24617","article-title":"Estimating breast cancer-specific and other-cause mortality in clinical trial and population-based cancer registry cohorts","volume":"115","author":"Dignam","year":"2009","journal-title":"Cancer"},{"issue":"Pt 3","key":"10.1016\/j.tranon.2026.102960_bib0029","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.mce.2015.09.035","article-title":"Endocrine resistance in breast cancer\u2013an overview and update","volume":"418","author":"Clarke","year":"2015","journal-title":"Mol. Cell Endocrinol."},{"key":"10.1016\/j.tranon.2026.102960_bib0030","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.lungcan.2016.08.002","article-title":"Scan-associated distress in lung cancer: quantifying the impact of \u201cscanxiety","volume":"100","author":"Bauml","year":"2016","journal-title":"Lung Cancer"},{"key":"10.1016\/j.tranon.2026.102960_bib0031","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1016\/S1470-2045(22)00555-1","article-title":"Switch to fulvestrant and palbociclib versus no switch in advanced breast cancer with rising ESR1 mutation during aromatase inhibitor and palbociclib therapy (PADA-1): a randomised, open-label, multicentre, phase 3 trial","volume":"23","author":"Bidard","year":"2022","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.tranon.2026.102960_bib0032","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1056\/NEJMoa2502929","article-title":"First-line camizestrant for emerging ESR1 -mutated advanced breast cancer","volume":"393","author":"Bidard","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.tranon.2026.102960_bib0033","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioadv.2023.213476","article-title":"Hydroelectric actuator for 3-dimensional analysis of electrophoretic and dielectrophoretic behavior of cancer cells; suitable in diagnosis and invasion studies","volume":"151","author":"Moharamipour","year":"2023","journal-title":"Biomater. Adv."}],"container-title":["Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1936523326002962?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1936523326002962?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T03:35:17Z","timestamp":1790739317000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1936523326002962"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":33,"alternative-id":["S1936523326002962"],"URL":"https:\/\/doi.org\/10.1016\/j.tranon.2026.102960","relation":{},"ISSN":["1936-5233"],"issn-type":[{"value":"1936-5233","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Time-varying hazard rates reveal patterns of progression in HR+\/HER2\u2013 metastatic breast cancer: Towards risk-adapted monitoring","name":"articletitle","label":"Article Title"},{"value":"Translational Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tranon.2026.102960","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"102960"}}